Association of microRNA101 expression with clinicopathologic features and prognosis in colorectal cancer.
- Author:
Xianhua GAO
1
;
Wei ZHANG
;
Jie YUAN
;
Xiaowen XU
;
Jian HE
;
Chuangang FU
Author Information
- Publication Type:Journal Article
- MeSH: Adenoma; Colorectal Neoplasms; Disease-Free Survival; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; MicroRNAs; Multivariate Analysis; Neoplasm Staging; Prognosis
- From: Chinese Journal of Gastrointestinal Surgery 2015;18(4):365-369
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the microRNA101(miR101) expression and its clinical significance in colorectal cancer.
METHODSTissue microarrays containing 56 specimens of normal mucosa, 51 adenoma and 735 colorectal cancer were examined by locked nucleic acid in-situ hybridization(LNA-ISH) for miR101 expression. Relationship between miR101 expression and clinicopathologic parameters and prognosis of colorectal cancer patients were analyzed. Fresh frozen tissues containing 5 specimens of normal mucosa, 5 adenoma and 47 colorectal cancer were examined by RT-PCR to verify the accuracy of LNA-ISH.
RESULTSExpression of miR101 increased gradually from normal mucosa, adenoma to stage I colorectal cancer (all P<0.01), and decreased gradually from stage II(, stage III( to stage IIII( colorectal cancer (all P<0.01). Overexpression of miR101 was related with lower incidence of lymph node metastasis, lower metastasis rate, higher differentiation and lower recurrence rate (all P<0.01). Multivariate survival analysis demonstrated that miR101 expression was an independent prognostic factor of overall survival (HR=0.550, 95% CI: 0.351-0.863) and disease free survival(HR=0.562, 95% CI: 0.397-0.794) in colorectal cancer patients. Overexpression of miR101 predicted a better prognosis in colorectal cancer patients.
CONCLUSIONSExpression of miR101 is associated with the genesis and development of colorectal cancer, and may serve as an independent prognostic factor for colorectal cancer patients.
